1. (a) “Antiretroviral therapy” means the treatment of patients prophylactically or with known retroviral infections with a combination of drugs to suppress the virus and stop the progression of the disease.
2. (b) “Assisted reproductive technology” (ART) means conception promoted by artificial or partially-artificial means, such as in vitro fertilization and intrauterine insemination.
3. (c) “Reactive” means the diagnostic finding that antibodies to an infectious disease have been detected in an individual in response to an infectious agent, such as HIV or HTLV.
4. (d) “Serodiscordant” means a sperm donor and recipient who differ in their antibody screening tests for sexually transmitted diseases, in which one tests reactive and the other, nonreactive.
5. (e) “Sexually transmitted infections” means viral infections that can be transmitted through sexual contact, including human immunodeficiency viruses (HIV) types 1 and 2, human T-cell lymphotropic viruses (HTLV) types 1 and 2, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), Epstein Barr virus (EBV), herpes simplex virus (HSV) type 2, and human herpes viruses (HHV) types 6 and 8.
6. (f) “Sperm washing” means the process of separating sperm from the seminal fluid by centrifugation and re-suspension, density gradient centrifugation, direct swim-up techniques, or other processes that render sperm free from seminal fluid.

The following definitions shall apply to Group 10:

Note: Authority cited: Sections 1639, 1644.5 and 131200, Health and Safety Code. Reference: Sections 1644.5, 131050 and 131051, Health and Safety Code.

History

1. New group 10 (sections 1235-1237) and section filed 10-19-2017; operative 9-6-2017 pursuant to Health and Safety Code section 1644.5(c)(3)(B)(ii). Submitted to OAL for as a file and print only pursuant to pursuant to Health and Safety Code section 1644.5(c)(3)(B)(ii) (Register 2017, No. 42).